Latest Commercial Growth News

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

Alpha HPA Limited has announced key leadership changes, appointing Rob Williamson as Managing Director and repositioning Rimas Kairaitis as Executive Director and Chief Commercial Officer to support its next growth phase.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.

First Graphene Limited strengthens its financial footing with a UK R&D tax rebate and expands its global footprint through new distribution agreements in India and Brazil.

HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.

Pointerra has won a US$2 million contract extension from the US Department of Energy to expand its hurricane impact analysis program, leveraging its Pointerra3D digital twin technology to enhance electric grid resilience across North America.